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• As HE4 and CA125 levels are usually normal in AGCTs, these cannot be used to exclude malignant ovarian tumors.
• Inhibin B is the most accurate single marker for the diagnosis and follow-up of AGCTs.
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Available online 18 November 2016Objective. Evaluation of circulating tumor markers in ovarian cancer is crucial for optimal patient care. The
goal of this study was to verify the most accurate circulating tumor markers for the diagnosis and follow-up of
adult-type granulosa cell tumors (AGCTs).
Methods. The levels of circulating human epididymis protein 4 (HE4) and carbohydrate antigen 125 (CA125),
together with AGCTmarkers inhibin B and anti-Müllerian hormone (AMH), weremeasured in 135 samples from
AGCT patients, 37 epithelial ovarian carcinoma (EOC) patients, and 40 endometrioma (ENDO) patients. The
levels were plotted with receiver operating characteristic (ROC) graphs, and the area under the curves (AUC)
of the different markers were calculated and compared.
Results. HE4 levels were signiﬁcantly lower in AGCTs than in EOCs (p b 0.0001). CA125 levels were above
35 IU/l in 25% of AGCT patients and 47.5% of ENDO patients, whereas inhibin B and AMH levels were elevated
only in patients with AGCTs. In the AUC comparison analyses, inhibin B alone was sufﬁcient to differentiate
AGCT from EOC. In differentiating AGCT from ENDO, inhibin B and AMH performed similarly, and the combina-
tion of inhibin B and AMH increased the accuracy compared to eithermarker alone (sensitivity, 100%; speciﬁcity,
93%). Among AGCT patients, inhibin B was the best marker for detecting the presence of AGCT.
Conclusions. HE4 and CA125 levels were low in AGCTs, and inhibin B was the most accurate circulating bio-
marker in distinguishing AGCTs from EOCs and from ENDOs. Inhibin B was also the best single marker for
AGCT follow-up.
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lä).1. Introduction
Differential diagnostics of an ovarian tumor is a common, albeit de-
manding clinical challenge, and critical for optimal patient care [1,2].
Table 1
Sample details (n).
AGCT
EOC ENDOWD DF
36 99 37 40
Year of sample retrieval 2007–2011 2007–2011 2009–2014 2005–2007
Age of the patient at sample
retrieval, yearsa
60 (36–80) 59 (25–86) 61 (29–79) 32 (26–47)
Primaryb 17 n/a 37 40
Stage I 17 n/a 5 0
Stage II 0 n/a 3 0
Stage III 0 n/a 16 15
Stage IV 0 n/a 16 24
Recurrentc 19 n/a 0 0
PreMPc,d 6 12 7 40
PostMPc,d 30 87 30 0
Abbreviations: WD; with disease, DF; disease-free, n/a; not applicable, MP; menopausal.
a Median (range).
b Staging according to FIGO 2009 inAGCTs and EOCs, and according to AmericanSociety
for Reproductive Medicine in ENDOs. Stage is available only for primary tumors in WD-
group, as in the surgery of recurrent tumors staging procedure is not performed.
c Serial samples from multiple recurrences.
d MP status at sample retrieval; “premenopausal” (PreMP) if the patient had and one or
two ovaries, and menopause was not indicated in the medical records, and “postmeno-
pausal” (PostMP) if the both ovaries had been removed, or thepatientwas postmenopaus-
al according to medical history.
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tures, and laboratory analyses are involved in evoking the suspicion of
a potentially malignant ovarian tumor. Circulating tumor markers,
such as carbohydrate antigen 125 (CA125), are commonly utilized to
evaluate the risk of malignancy of the most common ovarian tumors
of epithelial origin [3,4]. In the differential diagnosis of pelvic masses,
human epididymis protein 4 (HE4) is considered to be superior to
CA125 because the levels of HE4 are less inﬂuenced by the presence of
endometriomas and other benign ovarian tumors [5–7]. Furthermore,
HE4 shows better diagnostic sensitivity in the early stages of epithelial
ovarian carcinomas (EOCs) [8,9]. However, nontumor-related factors,
such as smoking, aging, and renal impairment, speciﬁc to individual pa-
tients, may also lead to increased HE4 levels [10,11] Speciﬁc algorithms
have been developed to enhance the diagnostic potential of single
serummarkers. These include theRisk ofMalignancy Index,which com-
bines sonographic ﬁndings, menopausal status, and serum CA125 levels
[12], and the Risk of OvarianMalignancy Index, which combines CA125
andHE4 levels with themenopausal status in amathematical algorithm
[13]. Although several studies have compared the diagnostic perfor-
mance of these algorithms, no clear conclusions have been drawn re-
garding their superiority [8,14,15].
After EOCs, adult-type ovarian granulosa cell tumors (AGCTs) are the
second-most common ovarian malignancy, representing 5% of all ovar-
ian cancers. AGCTs are generally detected at an early stage and are treat-
able with curative surgery [16–18]. The prognosis of AGCTs is usually
excellent, with 97–98% 5-year survival [17,18]. However, every third
patient, even those with early-stage AGCTs, relapses, and half of those
patients die due to the disease [17,18]. Although the histological diagno-
sis of AGCT can be difﬁcult, a unique somatic mutation in FOXL2 has
been shown to assist in unequivocal diagnosis [19,20]. Inhibin B and
anti-Müllerian hormone (AMH, also known as Müllerian-inhibiting
substance) have been established as follow-up markers for AGCTs [21,
22]. Among EOCmarkers data concerning AGCTs are limited. According
to two reports, CA125 has been reported to be elevated in a subset of
AGCTs [23,24]. HE4 is a relatively novel serum marker for ovarian can-
cer, and its levels in AGCTs are unknown.
Thus far only few studies have been focusing on the preoperative
evaluation and differential diagnosis AGCTs from other ovarian tumors
[23]. Further, the available differential diagnostic algorithms (e.g., the
Risk of Ovarian Malignancy Index) have been developed solely for epi-
thelial carcinomas. National Cancer Center Network (NCCN) guidelines
suggest that inhibin could bemeasuredwhen less common ovarianma-
lignancies are suspected [4]. However, the evidence behind the guide-
lines on AGCTs is sparse, and there is a need for a comparative
analysis of circulating tumor markers that can be utilized in differential
diagnostics of AGCTs. Also, after the suspicion of anAGCT andduring the
post-treatment follow-up, there is inconsistent evidence on the pre-
ferred tumor marker [25]. Utilizing a large prospective cohort of AGCT
patients and controls, this study aimed to evaluate the levels of circulat-
ing tumor markers HE4, CA125, inhibin B, and AMH and their ability to
differentiate AGCTs from other ovarian tumors at diagnosis. An addi-
tional aim was to determine their potential roles as circulating bio-
markers, as well as validate a novel detection method for AMH, in the
follow-up of AGCT patients.
2. Materials and methods
2.1. Patients and serum samples
Altogether 135 serial blood samples were obtained from 82 AGCT
patients treated at the Department of Obstetrics and Gynecology, Hel-
sinki University Central Hospital. From 2007 onwardswe have collected
blood samples from consenting patients with veriﬁed AGCT, and all the
available samples drawn during 2007–2011 were included into the
study. All AGCTs were tested positive for the FOXL2 (c.402CNG;
C134W) mutation. Clinical data were collected from the patients'medical records, including data on smoking and blood creatinine levels,
which are known to affect the interpretation of data on some of the
studied tumor markers. The patients were diagnosed between 1962
and 2009, and staging of the primary tumors was done according to
the FIGO 2009 criteria. The median size of the AGCTs was 7.0 cm
(range 2.0–40.0 cm). The median follow-up time of the AGCT patients
after blood sampling was 4.7 years (2.3–6.4 years). The ethics commit-
tee of Helsinki University Central Hospital and the National Supervisory
Authority for Welfare and Health in Finland approved the study, and all
the patients gave their informed consent.
The preoperative and prechemotherapy samples were obtained from
the AGCT patients within a month before surgery or chemotherapy, and
the follow-up samples were obtained during routine clinical follow-up
visits, after a minimum of three months from tumor treatment. The
AGCT samples were dichotomized according to the presence of macro-
scopic disease (with disease [WD] or disease-free [DF]) as evidenced at
the operation or by imaging with ultrasound or computer tomography
and a clinical examination. Clinical follow-up visits included a gynecolog-
ic examination and ultrasonography and other imaging when indicated.
Inhibin B, but no othermarker levels,were available for the clinician dur-
ing the follow-up of the majority of the AGCT patients. The AGCT WD
group consisted of 28 preoperative samples, ﬁve samples drawn at the
onset of chemotherapy and three samples drawn during the follow-up.
In the AGCT DF group all the samples were drawn during the follow-
up. All the samples were also classiﬁed as follows according to the
patient's menopausal status at sample retrieval: “premenopausal” if the
patient had one or two ovaries and menopause was not indicated in
the medical records (e.g., cessation of regular bleeding, presence of
menopausal symptoms, use of hormonal replacement therapy) and
“postmenopausal” if both ovaries had been removed, independent of
age, or the patientwas postmenopausal according to hermedical history.
The sample details are summarized in Table 1.
To evaluate the role of circulating tumormarkers in differential diag-
nostics of AGCTs, marker levels in 36 AGCT (WD) samples were com-
pared to those in preoperative samples derived from 37 patients with
EOCs and 40 patients with ENDOs (Table 1). The samples were drawn
within one month before the surgery. The EOC tumors were classiﬁed
histologically as high-grade serous (n = 31, 84%), mucinous (n = 2,
5%), endometrioid (n = 3, 8%), or clear cell types (n = 1, 3%). The
ENDO group consisted of women undergoing surgery due to an ovarian
endometrioma. The ENDO group was signiﬁcantly different from the
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whereas the age distribution and menopause status of the AGCT and
EOC groups were similar (p N 0.05). In order to reveal the optimal fol-
low-up marker, the tumor marker levels in the 36 AGCT WD samples
were compared to the 99 AGCT DF samples. No post-treatment samples
were available from EOC and ENDO patients.
Serum and plasma samples were prepared and stored at −80 °C
until the analysis. Serum HE4 (pM) was analyzed using an enzyme-
linked immunosorbent assay (ELISA) (Fujirebio Diagnostics Inc.,
Malvern, PA, U.S.), according to the manufacturer's instructions. Serum
CA125 (IU/ml) levels were analyzed using a chemiluminescent micro-
particle immunoassay (Architect CA 125 II) on an Abbott Architect
i2000 system (Abbott diagnostics, Abbott Park IL, U.S.), and serum in-
hibin B (ng/l) levels were analyzed using an Inhibin B Gen II ELISA
(A81303), with inhibin B Gen II calibrators and controls (A81304)
(Beckman Coulter, CA, U.S.). Creatinine (μmol/l) levels were analyzed
using an enzymatic assay (Roche Modular 8000 clinical chemistry ana-
lyzer; Roche Diagnostics, Penzberg, Germany) in theHelsinki University
Hospital laboratory. The glomerular ﬁltration rate (GFR) was calculated
using the Chronic Kidney Disease Epidemiology Collaboration formula
[26]. AMH (ng/ml) levels were analyzed from plasma samples with an
ultrasensitive AMH ELISA (AL-105i) from AnshLabs (AnshLabs, Web-
ster, TX, U.S.).
The analyseswere performed using both continuous values and cut-
off levels. The cut-off level for HE4 was set on 150 pM according to the
manufacturer's instructions. Patients were regarded as having impaired
renal function if the GFRwas b60ml/min/1.73m2 [27]. The cut-off level
for CA125 was 35 IU/l. For inhibin B and AMH, the cut-off levels were
determined according to the manufacturers' instructions. For premeno-
pausal patients, the cut-off limits for inhibin B and AMH was b200 ng/l
and b13 μg/l respectively. For postmenopausal patients, the cut-off
limits were b16 ng/l and b0.2 μg/l, respectively.
3. Statistical analyses
The levels of the markers did not follow a normal distribution, and
the between-group comparisons were therefore analyzed using the
Mann–WhitneyU test or Spearman's Rho. Receiver operating character-
istic (ROC) curves were constructed, and the area under the curve
(AUC) values were calculated, together with their 95% conﬁdence inter-
vals. All the study samples were included in the ROC analyses. Due to
the rarity of the disease, multiple circulating tumor marker measure-
ments (both pre-treatment (WD) and follow-up (WD or DF) samples)
of the AGCT patients were included to increase the precision of the esti-
mates of sensitivity and speciﬁcity. As the repeatedmeasurements-ROC
curves gave falsely optimistic estimates, the measurements were uti-
lized as independent data. Thus, the ROC curves should be viewed as0,1
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Fig. 1. The concentrations of HE4 (A), CA125 (B), inhibin B (C), and AMH (D) levels in AGCTWD
measurements of individual patients. The black dots represent premenopausal patients, and the
dashed lines. The levels of the marker are represented on a logarithmic scale. In comparison
**p b 0.0001. Abbreviations: AGCT, adult-type granulosa cell tumor; WD, with disease; DF, disedescriptive only. For the ROC-curve calculations, observations below
the detection limit were replaced with DL/2 values. Correlated ROC
curves were compared nonparametrically [28]. The associations be-
tween continuous variables and disease status (AGCT WD, EOC, ENDO,
AGCT DF) were studied using a mixed model repeated measures analy-
sis if all the values were above the detection limit and with a mixed ef-
fects Tobit model [29] if some variables were below the detection limit.
For the ROC analysis using the cut-off data the samples were
dicotomized as either high or normal based on the aforementioned
cut-off-levels. Statistical analyses were done using JMP Pro, version
11.0 and SAS, version 9.3 (SAS Inc., Cary, NC, U.S.).
4. Results
4.1. HE4 and CA125 levels were lower in AGCT patients than in EOC
patients: high levels indicated a malignant tumor of epithelial origin
HE4 levels were signiﬁcantly elevated in the EOC group when com-
pared to those of the other groups (p b 0.0001 in all pairwise compari-
sons). Furthermore, HE4 levels were increased in both AGCT WD and
DF patients when compared to ENDO patients due to the younger
mean age of the patients in the ENDO group. Interestingly, HE4 levels
were also higher in AGCTWD patients when compared to AGCT DF pa-
tients (p = 0.034). HE4 levels were correlated positively with serum
creatinine levels (Supplemental Fig. S1). After excluding patients with
renal insufﬁciency (estimated GFR ≤ 60ml/min/1.73m2), the results re-
vealed no statistical difference in HE4 levels between the AGCTWD and
DF patients, whereas the differences between the other groups were
sustained (data not shown).
HE4 levels were above the reference limit (150 pM) in only four
AGCT patients (Supplemental Table S1). Apart from one (a young pa-
tient; aged 25 years), all of these patients had impaired renal function
based on a decreased GFR. In the AGCT WD group only one patient
had high HE4 level reaching 256.1 pM, which could be explained by a
chronic glomerulonephritis and renal impairment. Elevated HE4 levels
were measured also in her two DF samples (197.4 pM and 375.6 pM).
The serum HE4 levels of the AGCT patients did not correlate with
tumor size or tumor stage (data not shown).
In common with HE4 levels, serum CA125 levels were signiﬁcantly
higher in patients with EOCs compared to AGCTs (Fig. 1B). The CA125
levels were also signiﬁcantly increased in AGCTWD patients compared
to DF patients (p= 0.0001). However, the elevation in CA125 levels of
the AGCTWD patients was verymodest, with only 25% of the levels ex-
ceeding the limit of 35 IU/l. The levels of the AGCT WD and ENDO pa-
tients were similar. The levels of CA125 were elevated in three
samples (CA125 37–71 IU/l) obtained from one AGCT patient (ID
159), probably due to simultaneous endometriosis. Interestingly, one0,2
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s between the groups, the asterisks indicate signiﬁcant statistical difference. *p b 0.05,
ase free; EOC, epithelial ovarian carcinoma; ENDO, endometrioma.
86 U.-M. Haltia et al. / Gynecologic Oncology 144 (2017) 83–89patient (ID 122) had extremely high CA125 levels: 5400 IU/ml (WD)
and 696 IU/ml (DF). No speciﬁc explanations for these high levels
were found, and the differences between groups remained the same
when this patient was excluded as an outlier from the analysis. CA125
levels did not correlate with tumor size or stage in the AGCT patients
(data not shown).
4.2. Inhibin B and AMH levels were increased in patients with AGCTs
Utilizing this prospective series, roles of inhibin B and AMHwere an-
alyzed in the diagnostic setting of AGCTs. Inhibin B andAMH levelswere
signiﬁcantly higher in AGCT WD patients when compared to those of
EOC and ENDO patients (Fig. 1). Inhibin B and AMH levels were also
higher in ENDO patients when compared to those of the AGCT DF and
EOC groups. These ﬁndings are related to the characteristics of the
ENDO group (i.e., mainly younger patients, with functional ovaries).
Among the ENDO patients, 1/40 (2.5%) had elevated inhibin B levels,
and 2/40 (5%) had elevated AMH levels above the normal range. Inhibin
B and AMH levels were also higher in AGCT WD samples when com-
pared to DF samples, conﬁrming their roles as markers in the follow-
up of AGCT patients.
4.3. Inhibin Bwas themost accurate single preoperativemarker to differen-
tiate AGCTs from EOCs and ENDOs
Toevaluate theperformance of the individualmarkers and combina-
tions of markers in the differential diagnostics of AGCT, receiver operat-
ing characteristic (ROC) curve analyses were performed, ﬁrst using the
continuous value data. In differentiating AGCTs from EOCs, all single
markers were highly accurate, with AUCs between 0.92 and 0.97, and
combinations of the markers did not improve their accuracy (Fig. 2A).
In distinguishing AGCTs from ENDOs, the accuracies of single markers
were lower, and combining the markers seemed to improve their per-
formance (Fig. 2B). When evaluating the markers in the follow-up of
AGCT patients, the accuracies of inhibin B and AMH were higher than
those of the other single markers (Fig. 2C).
To validate these ﬁndings, ROC-AUC analyseswere performed, using
dichotomized values by cut-off levels for eachmarker. In differentiating
AGCTs from EOCs, all the markers performed well, with AUC valuesHE4                                 
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disease free; EOC, epithelial ovarian carcinoma; ENDO, endometrioma.between 0.86 for CA125 and 0.96 for inhibin B (Supplemental Fig. S2).
In discriminating AGCTs from ENDOs, the utilization of the cut-off levels
improved the accuracy of the markers, especially that of inhibin B and
AMH. Combining inhibin B with any of the markers resulted in AUC
values close to or 1.0, indicating high accuracy in all the patient groups.
In ROC-AUC comparison analyses using the dichotomized data, in-
hibin B was the most accurate single marker in the primary diagnosis
of AGCTs, and there was no beneﬁt in adding other markers to inhibin
B when differentiating between AGCTs and EOCs (Table 2). Similar re-
sults were obtained in ROC-AUC comparison analyses using continuous
value data (data not shown). Of the epithelial markers, HE4 and CA125
were equally accurate in distinguishing between AGCT and EOCs. In dif-
ferentiating between AGCTs and ENDOs, inhibin B and AMH performed
equally well. However, adding AMH to inhibin B signiﬁcantly increased
the accuracy compared to inhibin B (p = 0.036) or AMH (p = 0.004)
alone, resulting in sensitivity of 100% and speciﬁcity of 93% (Table 3).
During AGCT follow-up, inhibin B performed as well as AMH as a single
marker (Table 2). Inhibin B and AMH together were superior to AMH
alone (p= 0.001) but not inhibin B alone (p N 0.05).
5. Discussion
AGCTs constitute a unique entity of ovarian-sex cord stromal-de-
rived neoplasms, originating from the granulosa cells of the ovary.
Based on the present study, inhibin B is the preferred marker for differ-
ential diagnostics and follow-up of AGCTs. Further, the levels of epithe-
lial ovarian cancer markers HE4 and CA125 are usually below normal
reference limits in AGCT patients. As the knowledge on the origins of
ovarian cancer has increased [30,31], we nowadays appreciate that the
different ovarian cancer subtypes have divergent diagnostic paths and
expression levels of circulating tumor markers [32,33]. The differential
diagnostics delineates the referral of patients with suspected ovarian
cancer to specialized centers, which is associated with signiﬁcantly im-
proved survival, underlining the value of accurate preoperative diag-
nostics [1,2]. Although relatively rare, ovarian AGCTs are malignant,
with a tendency toward late recurrence in up to 30% of cases, leading
to increased mortality [17,18]. Surgery and complete tumor removal
are the cornerstones in the treatment of both primary and relapsed dis-
ease and determine the survival of AGCT patients [34]. Spontaneous or0.75 1.00
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Table 2
p-Values of the AUC comparisons using cut off values.
Marker
AGCT vs EOC AGCT vs ENDO AGCT WD vs DF
HE4b CA125b Inh Bb AMHb HE4b CA125b Inh Bb AMHb HE4b CA125b Inh Bb AMHb
HE4a ns ns ns ns b0.0001b b0.0001b 0.021b b0.0001b b0.0001b
CA125a ns 0.046b ns ns b0.0001b b0.0001b 0.021a b0.0001b b0.0001b
Inh Ba ns 0.046a ns b0.0001a b0.0001a ns b0.0001a b0.0001a ns
AMHa ns ns ns b0.0001a b0.0001a ns b0.0001a b0.0001a ns
Inh B HE4a 0.005a 0.001a ns 0.018a b0.0001a b0.0001a ns ns b0.0001a b0.0001a ns ns
Inh B CA125a 0.006a 0.0004a ns 0.009a b0.0001a b0.0001a 0.041a 0.044a b0.0001a b0.0001a ns ns
Inh B AMHa 0.005a 0.0004a ns 0.008a b0.0001a b0.0001a 0.036a 0.004a b0.0001a b0.0001a ns 0.001a
Inh B HE4 CA125a 0.005a 0.0004a ns 0.008a b0.0001a b0.0001a 0.041a 0.045a b0.0001a b0.0001a ns ns
Inh B HE4 AMHa 0.005a 0.0004a ns 0.008a b0.0001a b0.0001a 0.036a 0.004a b0.0001a b0.0001a ns 0.001a
Inh B CA125 AMHa 0.005a 0.0004a ns 0.008a b0.0001a b0.0001a 0.045a 0.003a b0.0001a b0.0001a ns 0.0008a
The index in the p-value indicates the signiﬁcantly superior marker.
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to Stage Ic tumor, results in a signiﬁcantly increased risk of relapse [18,
35]. This further emphasizes the importance of pretreatment evalua-
tions in ensuring that patients with suspected AGCTs are referred to
specialized oncology units.
To improve the differential diagnosis and treatment of patients with
AGCTs, the present study evaluated a panel of serum markers in an
established AGCT patient cohort [36]. Although the cohort size of this
study may be limited, the circulating biomarkers studied herein have
not been examined in any larger, molecularly veriﬁed AGCT cohorts. In-
terestingly, recent evidence pointed to the utility of a 402CNGmutation
in the FOXL2 gene in circulating tumor DNA in the diagnosis of AGCTs in
30% of patients [37]. Although this diagnostic method is highly speciﬁc,
its clinical utilization is compromised by a laborious assay and low sen-
sitivity. Thus, circulating biomarkers are needed in the clinical preoper-
ative diagnostics of ovarian tumors.
Consistent with the lack of HE4 protein expression in AGCT tissue
[32] serumHE4 levelswere elevated in only aminority of AGCT patients
in the present study. Serum HE4 levels were positively associated with
creatinine levels, consistent with previous suggestions that renal insuf-
ﬁciency, smoking, and aging can all increase the levels of HE4 [10,11]. In
the present AGCT cohort, a signiﬁcant proportion of high HE4 levels
could be explained by impaired renal function, underlining the impor-
tance of simultaneous creatinine measurements when evaluating HE4
levels, especially in older patients. HE4 levels are not elevated in
endometriomas or other benign tumors [5,6], and the HE4 marker is
consideredmore speciﬁc than CA125 in EOCs [6]. Moreover, HE4 ﬂuctu-
ates very little during themenstrual cycle and is unaffected by common-
ly used hormonal medications [38]. Clinically, the ﬁndings of the
present study are consistent with those in the literature [5,6], with
high HE4 levels clearly indicating a malignant epithelial tumor.
It is important to keep inmind that normal HE4 levels do not rule out
ovarian malignancy. In the present study, in common with the ﬁndings
for HE4, high CA125 levels were indicative of EOCs, and CA125 levelsTable 3
Sensitivities and speciﬁcities of markers and marker combinations.
AGCT vs EOC AGCT
n = 73 n =
Sensitivity (%) Speciﬁcity (%) Sensi
HE4 97 84 3
Ca125 75 97 75
Inhibin B 92 100 92
AMH 100 83 83
InhB and HE4 92 100 92
InhB and CA125 100 97 92
InhB and AMH 100 100 100
InhB, HE4 and CA125 100 100 92
InhB, HE4 and AMH 100 100 100
InhB, CA125, and AMH 100 100 100were mostly below normal reference limits in AGCTs. The slight eleva-
tion in CA125 levels in a subset of AGCTs (both WD and DF), as well as
in ENDO patients, alludes to the diminished speciﬁcity of CA125 as a
marker for epithelial ovarian tumors.
Although several reports have demonstrated the clinical utility of in-
hibin B and AMH in AGCT surveillance [25], the evidence on their role in
discriminating AGCTs from other ovarian tumors has been lacking. The
present study indicated that inhibin B was the most accurate marker
in differentiating AGCTs from EOCs and ENDOs. Regarding different
ovarian cancer subtypes, previous reports have shown that inhibin B
levels can be elevated in mucinous epithelial carcinomas [25]. In the
present study, two patients with mucinous carcinomas exhibited ele-
vated levels of both HE4 and CA125 and normal levels of inhibin B
(5.2 and 3.6 ng/l). A larger cohort of mucinous carcinomas is needed
to thoroughly evaluate the ability of inhibin B to differentiate AGCTs
from mucinous EOCs.
According to our previous report using different methodology and a
larger, mostly historical cohort [21], inhibin B and AMHmeasurements
performed equally in AGCT follow-up and their combination was supe-
rior to inhibin B alone. However, problems with AMH assays have pre-
cluded the clinical usability of the marker [39]. In the present study,
using a novel AMH assay [40], AMH performed as well as inhibin B in
the AGCT follow-up, but there was no signiﬁcant beneﬁt in combining
them. Nevertheless, there were fewer samples and a shorter follow-up
in the present when compared to the earlier study. We noted that
AMH measurements increased the accuracy of the differential diagnos-
tics of AGCTs in patients with ENDOs. Thus, measuring AMH levels, in
addition to inhibin B levels, might be useful in the differential diagnos-
tics of AGCTs from ENDOs in premenopausal patients. However, as the
sensitivity and speciﬁcity of inhibin B alone are already high, the clinical
relevance of combining itwithAMHmay beneﬁt only a limited subset of
patients.
We conclude that inhibin B is the most accurate marker for the pre-
operative diagnosis of AGCTs, as it is able to differentiate AGCTs fromvs ENDO AGCT WD vs DF
76 n = 135
tivity (%) Speciﬁcity (%) Sensitivity (%) Speciﬁcity (%)
100 97 5
48 25 96
98 92 98
95 83 92
98 92 98
98 92 98
93 100 92
98 92 98
93 100 92
95 100 92
88 U.-M. Haltia et al. / Gynecologic Oncology 144 (2017) 83–89both EOCs and ENDOs. To aid the preoperative diagnosis of a potential
AGCT, we recommend that inhibin B and AMH levels should be mea-
sured in premenopausal women and that inhibin B levels should be
measured in postmenopausal women. HE4 and CA125 levels are gener-
ally low in AGCTs, and the patient's age, as well as creatinine levels and
GFRs, should be considered in the interpretation of HE4 levels. It is im-
portant to emphasize that amalignant ovarian tumor cannot be exclud-
ed based on normal levels of HE4 and/or CA125. Thus, themeasurement
of circulating biomarkers has a crucial role in ensuring optimal treat-
ment, including referral to a specialized oncology unit, for patients
with a clinical suspicion of ovarian cancer.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.ygyno.2016.11.018.
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